Anticus

Anticus Therapeutics is a biotechnology company dedicated to developing transformative cancer treatments by targeting the pathways that allow tumor cells to survive under stress and develop drug resistance. Founded by Dr. David Cheresh of UC San Diego, the company leverages decades of research into integrin signaling and its role in tumor initiation and metastasis. Their lead programs focus on inhibiting integrin alpha-V beta-3 and related pathways to re-sensitize resistant tumors to standard therapies, such as EGFR inhibitors. By addressing the stress-tolerant cells that drive recurrence, Anticus aims to improve long-term survival for patients with aggressive solid tumors.